Come and Meet LFB Group at BIO 2010 in Chicago French Pavilion Hall B2 - Booth 3712

PARIS--(EON: Enhanced Online News)--LFB is a European biopharmaceutical Group that develops, manufactures and markets Medicinal Products for the treatment of serious and often rare diseases in several major therapeutic fields, namely immunology, hemostasis and intensive care.

“Treatment of atypical Hemolytic Uremic Syndrome (aHUS) associated with an inherited abnormality of the complement system”

The French biopharmaceutical group LFB will be travelling to the BIO2010 congress in Chicago, to find:

Partners to co-develop its monoclonal antibodies (anti-CD20, anti-D) and recombinant transgenic proteins (FVIIa, FIX, AFP, Alpha-1-antitrypsin)
Products to develop: monoclonal antibodies and recombinant proteins in late pre-clinical or early clinical development stages in our therapeutic areas of interest, namely hemostasis, Immunology, Haemato-oncology and Intensive care.
Innovative technologies in the fields of expression, and purification of monoclonal antibodies and recombinant proteins.
Commercial partnerships for licensing-in hospital products for short term launch in France.
Collaborations for MAbgène, its GMP biomanufacturing affiliate (CMO).

LFB’s key achievements in 2009

February : Therapure Biopharma Inc. and LFB Biotechnologies announce a development services contract for a new therapeutic protein Therapure will apply its expertise to the development of an innovative plasma protein resulting from LFB’s research.
July: LFB BIOTECHNOLOGIES increased its stake in GTC Biotherapeutics, with an over all funding – through several financing structures – of 31M$. To date, the Group is holding 71% of GTC equity.
August: Marketing authorization filing in Germany for LFB WILLFACT®, factor von Willebrand.
September: First patient dosed in the phase II clinical trial of LFB monoclonal Anti-D (indicated for the prevention of fetomaternel RhD alloimmunization in rhesus negative women).
October 2009: Sanofi-Aventis and LFB announce a project of industrial cooperation for the manufacturing of biotech products within the alliance, and for CMO, contract offers to third parties.
MAbgène (LFB’s subsidiary) expands its GMP facilities to produce phase III clinical and commercial batches of biomolecules, with capacity up to 1000l disposables.
November 2009: LFB’s recombinant anti-CD20 monoclonal antibody is granted orphan drug status in Europe for Chronic Lymphocytic Leukemia.
December 2009: FDA grants Orphan Drug Designation to LFB’s « Complement Factor H» a human plasma-derived product, currently in pre-clinical development. The designated orphan indication is for the "Treatment of atypical Hemolytic Uremic Syndrome (aHUS) associated with an inherited abnormality of the complement system".
Marketing authorization filing on the French market for LFB CLAIRYG® (New Generation of Polyvalent immunoglobulin).
Thallion Pharmaceuticals Inc. and LFB Biotechnologies announced the signing of a definitive development and commercialization agreement for Shigamabs^®, Thallion’s product candidate for the treatment of Shiga toxin-producing E. coli, or STEC, infections.

About the LFB Group

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely immunology, hemostasis and intensive care. LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at international level and develop innovative therapies.
In 2009, LFB’s turnover reached €376 million; €76 million were dedicated to the group’s R&D activities. Christian Béchon is president and CEO of the LFB Group (1 700 employees).

http://www.lfb.fr